Literature DB >> 7730620

Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12.

H S Warren1, B F Kinnear, J H Phillips, L L Lanier.   

Abstract

Human NK cells produce IFN-gamma, TNF-alpha, and granulocyte macrophage-CSF when stimulated with susceptible target cells or through the CD16 and CD94 cell surface molecules. This study reports that NK cells also produce IL-5, a cytokine typically produced by Th2 cells, which mediates mobilization and differentiation of eosinophils. Polyclonal NK cell populations and NK cell clones produce IL-5 when stimulated to proliferate with gamma-irradiated MM-170 melanoma cells or JY B-lymphoblastoid cells and rIL-2. IL-5 is produced in cultures generated from freshly isolated NK cells (primary cultures) and when quiescent NK cells from primary cultures are restimulated to proliferate (secondary cultures). Production of IL-5 is on average 8.8-fold greater in secondary cultures compared with primary cultures (n > 18), suggesting that the ability of NK cells to produce IL-5 matures during primary stimulation. IL-5 secretion, particularly in primary cultures, is augmented by IL-4 and is inhibited by IL-12 and IL-10. By contrast, IL-4 and IL-12 have the reverse effects on IFN-gamma secretion. Cultured NK cells that no longer secrete cytokines can be restimulated to do so with either phorbol 12, 13 dibutyrate and ionomycin or with susceptible target cells in the presence of rIL-2. IL-5 production in these cultures occurs only when NK cells are in an exponential growth phase, whereas IFN-gamma, TNF-alpha, and granulocyte macrophage-CSF are produced also by stimulation of quiescent cells, although to a lesser extent. Furthermore, cytokine production is unrelated to the cytolytic activity of NK cells. In conclusion, proliferating human NK cells have the potential to produce IL-5 with secretion regulated by IL-4, IL-10, and IL-12.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730620

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

2.  Differential expression of cytokine genes in CD27-positive and -negative CD4 lymphocyte subsets from healthy humans and rheumatoid arthritis patients.

Authors:  I Stonãns; E Stonãne; H Vogelsang; U Junker; L Jäger
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

Authors:  Cyril Fauriat; Eric O Long; Hans-Gustaf Ljunggren; Yenan T Bryceson
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

4.  Protective role for interleukin-5 during chronic Toxoplasma gondii infection.

Authors:  Y Zhang; E Y Denkers
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Natural killer activating receptors trigger interferon gamma secretion from T cells and natural killer cells.

Authors:  O Mandelboim; S Kent; D M Davis; S B Wilson; T Okazaki; R Jackson; D Hafler; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 6.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

7.  Natural killer type 2 bias in remission of multiple sclerosis.

Authors:  K Takahashi; S Miyake; T Kondo; K Terao; M Hatakenaka; S Hashimoto; T Yamamura
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

8.  Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma.

Authors:  Matthew C Altman; Elizabeth Whalen; Alkis Togias; George T O'Connor; Leonard B Bacharier; Gordon R Bloomberg; Meyer Kattan; Robert A Wood; Scott Presnell; Petra LeBeau; Katy Jaffee; Cynthia M Visness; William W Busse; James E Gern
Journal:  J Allergy Clin Immunol       Date:  2018-03-05       Impact factor: 10.793

9.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

10.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.